MAXCYTE, Inc. (MXCT) intrinsic value & 10-year financials
MAXCYTE, Inc. (MXCT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 7.9% a year to $21.0M, with an average return on invested capital of -36.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.30
- Market cap
- $138.4M
- Revenue (FY2025)
- $21.0M
- Revenue growth (8-yr CAGR)
- 7.9%
- ROIC (10-yr avg)
- -36.1%
- Free cash flow (FY2025)
- -$36.2M
MXCT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $21.0M | -$44.6M | -$0.42 | -$36.2M | -247.6% | -24.6% |
| FY2024 | $22.2M | -$41.1M | -$0.39 | -$29.3M | -230.5% | -20.6% |
| FY2023 | $19.5M | -$37.9M | -$0.37 | -$25.4M | -247.7% | -16.4% |
| FY2022 | $28.7M | -$23.6M | -$0.23 | -$33.3M | -95.2% | -9.8% |
| FY2021 | $21.6M | -$19.1M | -$0.21 | -$14.5M | -84.3% | -15.4% |
| FY2020 | $15.5M | -$11.8M | -$0.17 | -$10.9M | -71.6% | -69.8% |
| FY2019 | $13.3M | -$12.9M | -$0.23 | -$10.1M | -93.7% | -96.0% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MAXCYTE, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MAXCYTE, INC. has historically struggled to out-earn its cost of capital, averaging just -36.1% ROIC.
MAXCYTE, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, MAXCYTE, INC. is modeled at 7.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-8.83 per share.